IL-38, a potential therapeutic agent for lupus, inhibits lupus progression

Article Immunology

IL-17 sustains the plasma cell response via p38-mediated Bcl-xL RNA stability in lupus pathogenesis

Kongyang Ma et al.

Summary: The study demonstrated the crucial role of IL-17 in enhancing plasma cell survival and promoting autoantibody production in the pathogenesis of SLE. This discovery may offer new therapeutic strategies for the treatment of SLE.

CELLULAR & MOLECULAR IMMUNOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Elevated IL-38 Serum Levels in Newly Diagnosed Multiple Sclerosis and Systemic Sclerosis Patients

Maryam Zarrabi et al.

Summary: The study found that serum levels of IL-38 were significantly higher in newly diagnosed or recently untreated patients with multiple sclerosis and systemic sclerosis compared to treated patients and healthy controls, suggesting a potential role of this cytokine in the development of these diseases or as part of a feedback loop to attenuate inflammation in the early stages.

MEDICAL PRINCIPLES AND PRACTICE (2021)

Add to Collection

Review Rheumatology

Cellular aspects of the pathogenesis of lupus nephritis

Anthony Chang et al.

Summary: Despite recent advances, there are still substantial unmet needs in the treatment of lupus nephritis. Non-white ethnicity remains a major risk factor. Recent findings suggest that tubulointerstitial inflammation and fibrosis are associated with renal outcomes, yet current treatment guidelines focus on glomerular inflammation. Combination therapies involving B-cell-targeted and calcineurin inhibitor have shown efficacy in trials, but response rates are modest. Understanding the pathogenesis of tubulointerstitial inflammation may lead to novel therapeutic targets for improving outcomes in patients with lupus nephritis.

CURRENT OPINION IN RHEUMATOLOGY (2021)

Add to Collection

Article Cell Biology

Interleukin-38 ameliorates poly(I:C) induced lung inflammation: therapeutic implications in respiratory viral infections

Xun Gao et al.

Summary: Our study demonstrates that IL-38 plays a crucial role in inhibiting exaggerated pulmonary inflammation during viral pneumonia, offering a novel therapeutic target for respiratory viral infections. Additionally, IL-38 can alleviate inflammatory responses by targeting genes associated with the host innate immune response to virus and counteracting the effects of IL-36 alpha in lung microenvironment.

CELL DEATH & DISEASE (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Immunobiological Properties and Clinical Applications of Interleukin-38 for Immune-Mediated Disorders: A Systematic Review Study

Abdolreza Esmaeilzadeh et al.

Summary: The exponential growth in cytokine usage as seroimmunobiomarkers has improved prognosis, early diagnosis, and immunotherapeutics. IL-38 plays a significant role in immunopathophysiological processes, and pre-clinical studies support its therapeutic potential in immune-mediated disorders. Collaboration between different medical specialists and researchers is recommended to advance knowledge in this field.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Interleukin-38 Suppresses Cell Migration and Proliferation and Promotes Apoptosis of Colorectal Cancer Cell Through Negatively Regulating Extracellular Signal-Regulated Kinases Signaling

Lifeng Huang et al.

Summary: IL-38 has been shown to potentially aid in early diagnosis and prognosis improvement in CRC, inhibiting CRC progression through negative regulation on the ERK signaling pathway.

JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2021)

Add to Collection

Article Immunology